Sangamo Biosciences (SGMO) Tops Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
BMO Capital Starts Sangamo BioSciences (SGMO) at Outperform
April 22, 2015 4:31 PM EDTBMO Capital initiates coverage on Sangamo BioSciences (NASDAQ: SGMO) with a Outperform rating and a price target of $19.00.
Analyst Jim Birchenough commented, "Our favorable outlook is based on its novel and proprietary approach to gene editing, a deep pipeline of gene therapy opportunities with competitive advantage,... More
